Return to homepagePandemic Pact

Task C1: A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Phase 1 Study of SARS-CoV-2 Therapeutics

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 75N93022D00016-P00002-759302300001-1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2023
    2024

  • Known Financial Commitments (USD)

    $219,169

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    CASEY LONG

  • Research Location

    United States of America

  • Lead Research Institution

    DYNPORT VACCINE COMPANY, LLC

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The Early Phase Clinical Trial Units provide a vehicle for investigation of new agents in the treatment and prevention of infectious diseases and can carry out all aspects of interventional clinical trial implementation.